This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| EudraCT | |
|---|---|
| Name | EudraCT |
| Type | Clinical trials database |
| Founded | 2004 |
| Headquarters | European Medicines Agency |
| Jurisdiction | European Union |
EudraCT
EudraCT is the European Union's clinical trials database for medicinal products, designed to record clinical trial applications and results across European Union member states. It interfaces with regulatory agencies such as the European Medicines Agency and national competent authorities including the Medicines and Healthcare products Regulatory Agency, the Agence nationale de sécurité du médicament et des produits de santé, and the Bundesinstitut für Arzneimittel und Medizinprodukte. The system supports harmonised reporting for sponsors, ethics committees such as the Central Ethics Committee model in some states, and international partners including the World Health Organization and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
EudraCT functions as a centralised repository linking submissions from sponsors, investigators, and authorised representatives to regulatory reviewers at institutions like the European Commission, the European Parliament, and national ministries of health such as the Ministry of Health (France), Bundesministerium für Gesundheit, and Ministero della Salute. The database records trial identifiers that connect to protocol documents, investigational medicinal products overseen by agencies such as European Directorate for the Quality of Medicines & HealthCare and sponsor organisations including GlaxoSmithKline, Roche, Pfizer, AstraZeneca, and academic centres like Karolinska Institutet and University College London. It complements regional registries such as ClinicalTrials.gov, ISRCTN Registry, German Clinical Trials Register, and EUCTR-related platforms.
EudraCT was established under legislative initiatives led by the European Commission in response to directives such as the Directive 2001/20/EC and later regulations framed by the Regulation (EU) No 536/2014. Early development involved collaboration with agencies including the European Medicines Agency and national competent authorities like the AIFA and Fimea. Major milestones include integration efforts coinciding with policy debates in institutions such as the European Parliament and implementation timelines set by the Council of the European Union. Subsequent updates were influenced by stakeholder consultations involving pharmaceutical companies like Novartis, academic networks such as the European Clinical Research Infrastructure Network, and international standards bodies including the International Organization for Standardization.
The database schema stores protocol metadata, sponsor details, trial sites, and investigational medicinal product information linking to organisations such as European Directorate for the Quality of Medicines & HealthCare and investigational sites like Charité – Universitätsmedizin Berlin, Hospital Clínic de Barcelona, and Hôpital Necker–Enfants Malades. Records include trial phases, comparable to classifications used by Food and Drug Administration and trial identifiers utilising standards from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Data fields reference ethics approvals from bodies like Committee on Human Research in various jurisdictions and safety reporting frameworks aligned with agencies such as the Pharmacovigilance Risk Assessment Committee.
EudraCT operates within the regulatory architecture created by instruments such as Directive 2001/20/EC and Regulation (EU) No 536/2014, and under governance influenced by the European Medicines Agency and the European Commission. Its legal basis intersects with national legislation enacted by parliaments like the French National Assembly, the Bundestag, and the Italian Parliament. The system supports compliance with inspection activities by authorities such as the European Court of Auditors and contributes to regulatory decisions involving marketing authorisations considered by committees like the Committee for Medicinal Products for Human Use. It also informs policy discussions in forums such as the Council of the European Union and advisory bodies including the European Patients' Academy on Therapeutic Innovation.
Access to EudraCT data is mediated by roles for sponsors, authorised users, and regulators from institutions like the European Medicines Agency and national agencies such as the Medicines and Healthcare products Regulatory Agency. Data protection obligations reference frameworks including the General Data Protection Regulation and oversight by national data protection authorities such as the Commission Nationale de l'Informatique et des Libertés and the Bundesbeauftragte für den Datenschutz und die Informationsfreiheit. Publication policies intersect with transparency initiatives endorsed by bodies like the European Ombudsman and advocacy organisations including Transparency International and patient groups such as the European Patients' Forum.
EudraCT interoperates with the Clinical Trials Information System, a platform developed by the European Medicines Agency to implement Regulation (EU) No 536/2014 and coordinate trial authorisation workflows among national competent authorities like the Agence nationale de sécurité du médicament et des produits de santé and the Agenzia Italiana del Farmaco. The integration supports parallel processes involving ethics committees such as those modelled on the Central Medical Ethics Committee and global registries including ClinicalTrials.gov and WHO International Clinical Trials Registry Platform. Strategic alignment involved contributions from stakeholders like European Commission policy units, pharmaceutical companies including Sanofi and Bayer, and academic consortia such as European Research Infrastructure Consortium participants.
EudraCT has been credited with improving harmonisation across regulators like the European Medicines Agency and national competent authorities including the Fimea and AIFA, aiding sponsors from organisations such as Johnson & Johnson and universities like Oxford University. Criticisms have addressed transparency, timeliness, and data completeness raised by civil society groups such as Health Action International and academic critics at institutions like London School of Hygiene & Tropical Medicine and University of Amsterdam. Debates before the European Parliament and advocacy from patient organisations including the European Patients' Forum and watchdogs like Transparency International have shaped reforms and further interoperability with systems such as ClinicalTrials.gov and national registries.
Category:European clinical research